Cilazapril
CARDIOVASCULAR SYSTEM
Also known as: cilazapril anhydrous, cilazapril hydrate, cilazapril monohydrate, cilazapril monohydrobromide, inhibace, vascace
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Cilazapril is a drug catalogued in DrugCentral. DrugCentral lists 1 molecular target, including ACE. Recorded indications include Hypertensive disorder.
- Molecular targets: ACE (1 listed in DrugCentral).
- Indications: Hypertensive disorder.
- ATC code: C09AA08 (ACE inhibitors, plain).
- Molecular formula: C22H31N3O5; molecular weight 417.51 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Hypertensive disorder
Mechanism & targets
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Angiotensin-converting enzyme | ACE | inhibitor | IC50 8.70 |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
C09AA08 | CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ACE INHIBITORS, PLAIN › ACE inhibitors, plain |
C09BA08 | CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ACE INHIBITORS, COMBINATIONS › ACE inhibitors and diuretics |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Amaurosis fugax | 873.2 |
| Ocular discomfort | 783.2 |
| Haemorrhagic stroke | 775.1 |
| Head discomfort | 739.1 |
| Urinary tract disorder | 715.9 |
| Blindness | 587.9 |
| Generalised oedema | 564.2 |
| Altered state of consciousness | 556.0 |
| Haematemesis | 551.1 |
| Eye pain | 548.0 |
| Tinnitus | 509.8 |
| Presyncope | 488.4 |
Chemical structure
| Molecular formula | C22H31N3O5 |
|---|---|
| Molecular weight | 417.51 g/mol |
| CAS number | 88768-40-5 |
| InChIKey | HHHKFGXWKKUNCY-FHWLQOOXSA-N |
| PubChem CID | 56330 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Cilazapril used for?
DrugCentral lists the following indications for Cilazapril: Hypertensive disorder.
How does Cilazapril work?
Its molecular targets in DrugCentral include ACE (inhibitor).
What is the chemical formula of Cilazapril?
Cilazapril has the molecular formula C22H31N3O5 and a molecular weight of 417.51 g/mol.
Browse: all drugs starting with C · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 641 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2104578 — compound record and bioactivity
- PubChem CID 56330 — chemical identifiers
- DrugBank DB01340 — drug record
- FDA UNII 19KW7PI29F — substance identity
- UniProt P12821 (ACE) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.